772 related articles for article (PubMed ID: 31540840)
1. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
[TBL] [Abstract][Full Text] [Related]
2. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya.
Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C
BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890
[TBL] [Abstract][Full Text] [Related]
3. Rapid situational assessment of people who inject drugs (PWID) in Nairobi and coastal regions of Kenya: a respondent driven sampling survey.
Oguya FO; Kenya PR; Ongecha F; Mureithi P; Musyoka H; Muraguri N; Mundia B; Angira C; Shose M; Basheeb TA; Mohamed AA; Oyore JP; Ochieng OG; Dida GO; Abdalla S; Abdool R
BMC Public Health; 2021 Aug; 21(1):1549. PubMed ID: 34391389
[TBL] [Abstract][Full Text] [Related]
4. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
[TBL] [Abstract][Full Text] [Related]
6. Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study.
Solomon SS; Mehta SH; Srikrishnan AK; Solomon S; McFall AM; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Lucas GM; Kumar MS; Sulkowski MS; Quinn TC
Lancet Infect Dis; 2015 Jan; 15(1):36-45. PubMed ID: 25486851
[TBL] [Abstract][Full Text] [Related]
7. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya.
Stone J; Fraser H; Walker JG; Mafirakureva N; Mundia B; Cleland C; Bartilol K; Musyoki H; Waruiru W; Ragi A; Bhattacharjee P; Chhun N; Lizcano J; Akiyama MJ; Cherutich P; Wisse E; Kurth A; Luhmann N; Vickerman P
AIDS; 2022 Dec; 36(15):2191-2201. PubMed ID: 36111533
[TBL] [Abstract][Full Text] [Related]
8. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya.
Kurth AE; Cleland CM; Des Jarlais DC; Musyoki H; Lizcano JA; Chhun N; Cherutich P
J Acquir Immune Defic Syndr; 2015 Dec; 70(4):420-7. PubMed ID: 26226249
[TBL] [Abstract][Full Text] [Related]
9. HIV, Hepatitis B and C among people who inject drugs: high prevalence of HIV and Hepatitis C RNA positive infections observed in Delhi, India.
Ray Saraswati L; Sarna A; Sebastian MP; Sharma V; Madan I; Thior I; Pulerwitz J; Tun W
BMC Public Health; 2015 Jul; 15():726. PubMed ID: 26223866
[TBL] [Abstract][Full Text] [Related]
10. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.
Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD012021. PubMed ID: 28922449
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of assisted partner services for people who inject drugs in Kenya to identify partners living with HIV and hepatitis C virus infection: a prospective cohort study.
Monroe-Wise A; Mbogo L; Sambai B; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Masyuko S; Scott J; Juma E; Macharia P; Kingston H; Sinkele W; Gitau E; Bosire R; Musyoki H; Herbeck J; Farquhar C
Lancet Glob Health; 2024 May; 12(5):e859-e867. PubMed ID: 38614633
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and associated risk factors of hepatitis C antibody and RNA among people who inject drugs in Puerto Rico.
Aponte-Meléndez Y; Eckhardt B; Fong C; Padilla A; Trinidad-Martínez W; Maldonado-Rodríguez E; Agront N; Mateu-Gelabert P
J Subst Use Addict Treat; 2024 May; 160():209308. PubMed ID: 38301921
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
[TBL] [Abstract][Full Text] [Related]
14. Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015.
Abara WE; Trujillo L; Broz D; Finlayson T; Teshale E; Paz-Bailey G; Glick S; Al-Tayyib AA; Robinson WT; Masiello-Schuette S; Sey EK; Anderson BJ; Poe J; Braunstein S
J Infect Dis; 2019 Jul; 220(3):377-385. PubMed ID: 30915477
[TBL] [Abstract][Full Text] [Related]
15. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots.
Hope VD; Hickman M; Ngui SL; Jones S; Telfer M; Bizzarri M; Ncube F; Parry JV
J Viral Hepat; 2011 Apr; 18(4):262-70. PubMed ID: 20456636
[TBL] [Abstract][Full Text] [Related]
16. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
17. Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs.
Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Turcotte MÈ; Bruneau J
Am J Prev Med; 2020 Jun; 58(6):845-853. PubMed ID: 32444003
[TBL] [Abstract][Full Text] [Related]
18. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
[TBL] [Abstract][Full Text] [Related]
19. Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya.
Akiyama MJ; Riback LR; Nyakowa M; Musyoki H; Lizcano JA; Muller A; Zhang C; Walker JG; Stone J; Vickerman P; Cherutich P; Kurth AE
Int J Drug Policy; 2023 Mar; 113():103959. PubMed ID: 36758335
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya: A qualitative study.
Akiyama MJ; Muller A; Huang O; Lizcano J; Nyakowa M; Riback L; Ross J; Bundi H; Kulabi ES; Mwangi AM; Musyoki H; Cherutich P; Kurth A
Glob Public Health; 2022 Jun; 17(6):1016-1028. PubMed ID: 33689563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
